FDA collaboration to improve safe use of fluoroquinolone antibiotics: an
| Autor: | John, Whyte, Scott, Winiecki, Christina, Hoffman, Kaushal, Patel |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
mesh:Prescription Drug Misuse
mesh:Inappropriate Prescribing education mesh:Medical mesh:Education mesh:Randomized Controlled Trials as Topic mesh:Drug Resistance mesh:Fluoroquinolones mesh:Bacterial mesh:Peer Influence mesh:Continuing mesh:United States Original Research mesh:Antimicrobial Stewardship |
| Zdroj: | Pharmacy Practice |
| ISSN: | 1885-642X |
| Popis: | Objective: This ex post facto matched control study was conducted to evaluate the effect of targeted short-form messages or continuing medical education (CME) on fluoroquinolone prescribing among high prescribers. Methods: A total of 11,774 Medscape healthcare provider (HCP) members prescribing high volumes of fluoroquinolones were randomized into three segments to receive one of three unique targeted short-form messages, each delivered via email, web alerts, and mobile alerts. Some HCPs receiving targeted short-form messages also participated in CME on fluoroquinolone prescribing. A fourth segment of HCPs participated in CME only. Test HCPs were matched to third-party-provider prescriber data to identify control HCPs. We used prescriber data to determine new prescription volume; percentage (%) of HCPs with reduced prescribing; new prescription volume for acute bacterial sinusitis (ABS), uncomplicated urinary tract infection (uUTI), and acute bacterial exacerbations of chronic bronchitis in those with chronic obstructive pulmonary disease (ABECB-COPD). Open rates for emailed targeted short-form messages were also measured. Results: Targeted short-form messages and CME each resulted in significant new prescription volume reduction versus control. Combining targeted short-form messages with CME yielded the greatest percentage of test HCPs with reduced prescribing (80.1%) versus controls (76.2%; p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|